•  

Published Articles

Amgen Deal in Re$earch Money

In their September 11, 2019 online edition as part of their "Innovation this Week" newsletter, Re$earch Money talked about TIAP's partnership agreement with Amgen: "A few days after celebrating its 10th anniversary and changing its name to Toronto Innovation Acceleration Partners (TIAP), the commercialization organization formerly known as MaRS Innovation announced a new collaboration with the biotechnology company Amgen. The aim of the collaboration is to identify and jointly fund disruptive technologies derived from discovery research conducted in Toronto and managed by ... Read more

BetaKit Article on Amgen Partnership

Jessica Galang of BetaKit, a Canadian online publication on start-up news and tech innovation, writes about TIAP's recently announced strategic partnership with Amgen.  Read more here: http://bit.ly/2lSDVYE   Read more

IP Protection for Antibody-based Assets in the Canadian Market and beyond

Together with Noel Courage, MI's Philip Goldbach co-authored an article published in BioTechnology Focus on IP rights and considerations surrounding antibody-based assets.  As the article states: Antibodies (immunoglobulins) and other antibody-derived biologics have become a mainstay of the biotechnology industry, both here in Canada and around the world. Novel antibodies are continuously being designed, modified, expressed and purified for a number of uses, including as therapeutics, diagnostics, or research tools. As is the case with other types of life science technologies, intellectual ... Read more